EHS rolls out tubeless insulin pump technology for children with Type 1 diabetes

Insulin pumps have existed for decades. But the gap between what the technology can do and what most patients in the region actually receive has remained stubbornly wide. That gap just got a little narrower in Sharjah.

Al Qassimi Women's and Children Hospital, operating under Emirates Health Services (EHS), has introduced the Omnipod 5 Automated Insulin Delivery System for children living with Type 1 diabetes. It is the first deployment of this technology across any EHS facility, and it signals a meaningful step forward in how the UAE's public health system approaches chronic disease management in younger patients.

The move fits squarely within the UAE's broader push to modernise its healthcare infrastructure. EHS has been expanding its use of advanced medical technologies across multiple specialties, and this rollout reflects that direction. For families managing Type 1 diabetes in a child, the stakes are high and the daily burden is real. A system that reduces that burden while improving clinical outcomes is not a small thing.

How does it work?

The Omnipod 5 is a tubeless, wearable insulin delivery system that communicates with a continuous glucose monitor to adjust insulin doses automatically. Unlike traditional pump systems, it requires no tubing and attaches directly to the skin. The system uses a built-in algorithm to read glucose data and respond in real time, increasing or reducing insulin delivery based on the child's current levels and trends.

Key features of the system include:

• Automated insulin adjustments without manual input from the patient or caregiver
• Tubeless design that is less intrusive for active children
• Integration with continuous glucose monitoring for real-time responsiveness
• Smartphone compatibility, allowing caregivers to monitor remotely

So the system does not simply deliver insulin on a fixed schedule. It learns, adjusts, and responds. For a child in school or at sport, that matters enormously.

Why does it matter?

Type 1 diabetes requires constant vigilance. Parents of children with the condition manage a relentless cycle of glucose checks, dose calculations, and intervention, often through the night. Automated insulin delivery systems reduce that cognitive load significantly. Studies have shown they also improve time-in-range metrics, the percentage of hours a patient spends within a healthy glucose window, which correlates directly with long-term health outcomes.

For EHS, this is also about equity. Introducing the Omnipod 5 within a public hospital means this technology is not limited to those who can afford private care. That distinction matters in a system serving a wide and diverse patient population.

The context

The UAE has one of the highest rates of diabetes in the world. While much of that burden falls on adults with Type 2 diabetes, Type 1 among children is a growing clinical priority. The country's Vision 2030-aligned health strategies, and EHS's own digital health agenda, have consistently pointed toward technology adoption as central to improving outcomes.

This launch is one data point in that larger effort. But for the families it directly affects, it is the most important one.